The cell surface receptors GHR and DA also serve as targets for the highly effective GHR antagonist pegvisomant and for DA used primarily in an adjunctive treatment setting, respectively, but there is less evidence regarding their use as markers of tumor aggressiveness. Here, GHR is linked to neoplasm.